"SGLT2 Inhibitors Not Linked To Kidney Injury"
People with Type 2 diabetes who take sodium-glucose cotransporter-2 (SGLT2) inhibitors are not at risk of acute kidney injury despite concerns, researchers have said. The medications have been shown to improve cardiovascular and renal outcomes in those who have Type 2 diabetes, however there have been medical alerts relating to the treatment. A team from the Icahn School of Medicine at Mount Sinai decided to investigate the real-world risk of AKI comparing SGLT2 inhibitor users and people who do not take them. They collected data from the Mount Sinai chronic kidney disease registry and for 1,207 users and 1,207 non-users in the Geisinger Health System cohort. The authors concluded: “Our findings do not suggest an increased risk of AKI associated with SGLT2 inhibitor use in patients with Type 2 diabetes in two large health systems.”
- The Icahn School of Medicine at Mount Sinai
Diabetes May Accelerate Blood Cancer Growth, Yet Survival Outcomes Differ by Race
Sep 29, 2023 View All Press Releases
Researchers Identify Potential Target for Treatment Among Patients With Type 2 Diabetes
Aug 04, 2022 View All Press Releases
SARS-CoV-2 Infection Likely Not Associated With Increased Risk of New-Onset Diabetes
Feb 22, 2022 View All Press Releases